SimBioSys is a digital health company applying AI to tumor biology to enable precision oncology. Its platform integrates multi-modal patient data to model tumor behavior and predict response to therapy. Partners with Ferrum Health (2026) to expand AI-powered surgical planning access.
SimBioSys said the FDA cleared TumorSight Risk, which the company describes as the first AI-powered, MRI-derived breast cancer recurrence risk assessment.